Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00467181 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery
A Phase 2 study, sponsored by Summa Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00467181 is a Phase 2 study that has completed, run by Summa Health System. The registered enrollment target is 30 participants.
The verdict
NCT00467181, a Phase 2 study, has completed, sponsored by Summa Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The Primary objective is to reduce the incidence of postoperative renal dysfunction in a high-risk subset of patients undergoing cardiac surgery on cardiopulmonary bypass with Fenolopam, a selective dopamine-1 receptor agonist. Perioperative renal function will be observed in 3 randomly selected groups of patients-Fenoldopam infusion at 0.03 cg/kg/min, Fenoldopam at 0.1 mcg/kg/min or placebo Secondary objective: will be to correlate Fenoldopam usage with postoperative clinical outcomes such as ICU stay, hospital stay, need for inotropes/vasopressors, need for diuretics, requirements for ECF at discharge, and overall perioperative cost reduction through decreased ICU and hospital length of stay.
Interventions
- DRUG Fenoldopam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00467181
The ClinicalTrials.gov registry entry for NCT00467181 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Summa Health System, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fenoldopam is the first listed.
NCT00467181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00467181 about?
NCT00467181 is a clinical study titled "A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery". The Primary objective is to reduce the incidence of postoperative renal dysfunction in a high-risk subset of patients undergoing cardiac surgery on cardiopulmonary bypass with Fenolopam, a selective dopamine-1 receptor agonist. Perioperative renal function will be observed in 3 randomly selected gro...
What is the current status of trial NCT00467181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00467181?
The interventions under investigation include: Fenoldopam (DRUG).
Who is sponsoring clinical trial NCT00467181?
This trial is sponsored by Summa Health System, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.